Association of Mannose-Binding Lectin Polymorphisms with Sepsis and Fatal Outcome, in Patients with Systemic Inflammatory Response Syndrome

Journal of Infectious Diseases

Volumn 188, Issue 9, 2003, Pages 1394-1403

  Garred, Peter ^a   Strøm, Jens J ^b   Quist, Lars ^b   Taaning, Ellen ^b   Madsen, Hans O ^a  

^a Rigshospitalet   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LECTIN; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FATALITY; FEMALE; GENETIC CORRELATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; IMMUNITY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERMINAL DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; DENMARK; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VARIATION (GENETICS);

EID: 0242551989     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379044     Document Type: Article

References (39)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273:117-23.
2. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112:235-43.
3. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29(Suppl 7):S109-16.
4. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282:561-8.
5. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-6.
6. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-3.
7. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556-60.
8. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor- 1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357:1096-7.
9. Turner MW, Hamvas RMJ. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2000; 2:305-22.
10. Sastry K, Herman GA, Day L, et al. The human mannose-binding protein gene: exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989; 170:1175-89.
11. Taylor ME, Brickell PM, Craig RK, Summerfield JA. Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. Biochem J 1989; 262:763-71.
12. Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337:1569-70.
13. Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Gen 1992; 1:709-15.
14. Madsen HO, Garred P, Kurtzhals JAL, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994; 40:37-44.
15. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155:3013-20.
16. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from Southeast Africa and South America. J Immunol 1998; 161:3169-75.
17. Koch A, Melbye M, Sorensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001; 285:1316-21.
18. Garred P, Madsen HO, Hofmann B, Svejgaard A. Increased frequency of homozygosity of abnormal mannan-binding protein alleles in patients with suspected immunodeficiency. Lancet 1995; 346:941-3.
19. Garred P, Madsen HO, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349:236-40.
20. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104:431-7.
21. Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358:614-8.
22. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2:442-50.
23. Graudal NA, Madsen HO, Tarp U, et al. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000; 43:515-21.
24. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-3.
25. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
26. Garred P, Madsen HO, Kurtzhals JAL, et al. Diallelic polymorphism may explain variations of blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet 1992; 19: 403-12.
27. Aldener-Cannava A, Olerup O. HLA-DPA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) and distribution of DPA1 alleles in Caucasian, African and Oriental populations. Tissue Antigens 1996; 48:153-60.
28. Naito H, Ikeda A, Hasegawa K, et al. Characterization of human serum mannan-binding protein promoter. J Biochem (Tokyo) 1999; 126:1004-12.
29. Moreno R, Apolone G. Impact of different customization strategies in the performance of a general severity score. Crit Care Med 1997; 25: 2001-8.
30. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-36.
31. Roy S, Knox K, Segal S, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359:1569-73.
32. Kronborg G, Weis N, Madsen HO, et al. Variant mannose-binding lectin alleles are not associated with susceptibility to and outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis 2002; 185:1517-20.
33. Soell M, Lett E, Holveck F, Schöller M, Wachsmann D, Klein J-P. Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen and mannan binding protein inhibits TNF-α release. J Immunol 1995; 154:851-60.
34. Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NJ. Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis 2001; 184:1152-62.
35. Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781-95.
36. Nauta AJ, Raaschou-Jensen N, Roos A, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33:2853-63.
37. Kirchfink M. Controlling the complement system in inflammation. Immunopharmacology 1997; 38:51-62.
38. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5:788-92.
39. Garred P, Pressler T, Lanng S, et al. Mannose-binding lectin (MBL) substitution in an MBL deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 2002; 33:201-7.